Is Toujeo (insulin glargine) a type of insulin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Toujeo Insulin?

Yes, Toujeo is insulin—specifically, it is insulin glargine 300 U/mL, a long-acting basal insulin analog used for treating both type 1 and type 2 diabetes mellitus. 1, 2

What Toujeo Is

  • Toujeo is a concentrated formulation of insulin glargine at 300 U/mL, which is three times more concentrated than the standard insulin glargine 100 U/mL (Lantus). 1

  • It functions as a long-acting basal insulin analog with a duration of glucose-lowering activity exceeding 24 hours. 2

  • The pharmacokinetic and pharmacodynamic profiles of Toujeo are flatter, longer, and more stable compared to insulin glargine 100 U/mL, with less intra- and inter-patient variability. 1

Clinical Classification

  • Toujeo belongs to the category of "new longer-acting basal analogs" (specifically U-300 glargine) that may confer lower hypoglycemia risk compared to U-100 glargine in individuals with type 1 diabetes. 3

  • Basal insulin analogs like Toujeo have longer duration of action with flatter, more constant plasma concentrations and activity profiles than NPH insulin. 3

Approved Uses

  • Toujeo is approved for once-daily subcutaneous administration in adults with type 1 and type 2 diabetes. 1, 2

  • For type 1 diabetes, Toujeo must be used as part of a basal-bolus regimen that includes mealtime rapid-acting insulin, as basal insulin alone would fail to control postprandial glucose excursions. 4

  • For type 2 diabetes, Toujeo can be used alone or in combination with oral antidiabetic agents or mealtime insulin depending on the patient's needs. 2

Important Clinical Distinctions

  • Toujeo and Lantus (insulin glargine 100 U/mL) are NOT bioequivalent, and daily insulin requirements are typically slightly higher with Toujeo than with standard insulin glargine. 1

  • Switching from another basal insulin to Toujeo may require dose adjustment and reinforcement of blood glucose monitoring. 1

  • Toujeo offers comparable glycemic efficacy to insulin glargine 100 U/mL but with a lower risk of nocturnal hypoglycemia, particularly in insulin-experienced patients with type 2 diabetes. 2

References

Research

[INSULIN GLARGINE 300 U/mL (TOUJEO®)].

Revue medicale de Liege, 2016

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Type 1 Diabetes Management with Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.